Connect Biopharma Holdings shares are trading higher after the company announced data at Week 48 from the Phase 2 trial for icanbelimod in patients with moderate-to-severe ulcerative colitis.
Portfolio Pulse from Benzinga Newsdesk
Connect Biopharma Holdings announced positive Week 48 data from the Phase 2 trial for icanbelimod in patients with moderate-to-severe ulcerative colitis, leading to a rise in its share price.

June 02, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Connect Biopharma's shares are trading higher after announcing positive Week 48 data from the Phase 2 trial for icanbelimod in patients with moderate-to-severe ulcerative colitis.
The positive Week 48 data from the Phase 2 trial for icanbelimod in patients with moderate-to-severe ulcerative colitis indicates that the drug is showing promising results. This news is likely to boost investor confidence in Connect Biopharma, leading to a short-term increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100